This patented technology is a method of treatment for gonorrhea that involves the use of a commensal, non-pathogenic microorganism that antagonizes and kills the bacterium responsible for causing gonorrhea.
Background: The CDC estimates that over 700,000 gonorrhea infections occur annually in the US alone. European officials have estimated that 10% of gonorrhea infections in Europe are now caused by antibiotic-resistant strains. The advent and proliferation of antibiotic-resistant gonorrhea has caused the CDC to revise its treatment guidelines, with ceftriaxone being the only currently recommended treatment option for gonorrhea in the US. New therapeutics are therefore actively sought and needed for the treatment of gonorrhea, especially antibiotic-resistant gonorrhea.
Applications:
Status: issued U.S. patent #10,286,016